View ValuationRenol Polychem 将来の成長Future 基準チェック /06現在、 Renol Polychemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長17.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (98% accrual ratio). Market cap is less than US$10m (₹611.7m market cap, or US$6.46m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.お知らせ • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).お知らせ • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.お知らせ • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation SBoard Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Renol Polychem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:RNPL - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202690283-626-402N/A12/31/202582067-368-249N/A9/30/202573752-109-95N/A6/30/202567851-93-86N/A3/31/202562650-13-12N/A3/31/202465151212N/A3/31/20234197-11-11N/A3/31/2022268222N/Aアナリストによる今後の成長予測収入対貯蓄率: RNPLの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RNPLの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RNPLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RNPLの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RNPLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RNPLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 11:48終値2026/07/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Renol Polychem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (98% accrual ratio). Market cap is less than US$10m (₹611.7m market cap, or US$6.46m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.
お知らせ • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.
New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).
お知らせ • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.
お知らせ • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation S
Board Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.